SCHEMBL19973530

SCHEMBL19973530

O=C(NC1CCOc2c(C(=O)Nc3ccc(F)c(F)c3)cccc21)c1ccncc1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.43
RAB9A P51151 4/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
HSD17B10 Q99714 1/20 0.42
CRACR2A Q9BSW2 2/20 0.42
NPC1 O15118 3/20 0.41
MAOB P27338 1/20 0.41
TRPV1 Q8NER1 3/20 0.40
TP53 P04637 2/20 0.40
AHR P35869 1/20 0.40
RXFP1 Q9HBX9 1/20 0.39
LMNA P02545 1/20 0.39
CASP3 P42574 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
HPGD P15428 1/20 0.39
KCNK3 O14649 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19973525 1.00 HTT (0.43) HTTRAB9ASMN1; SMN2HSD17B10CRACR2A
SCHEMBL19973987 0.90 L3MBTL1 (0.47) RAB9ASMN1; SMN2HSD17B10CRACR2ANPC1
SCHEMBL21175567 0.90 L3MBTL1 (0.47) RAB9ASMN1; SMN2HSD17B10CRACR2ANPC1
SCHEMBL19973433 0.86 TP53 (0.46) HTTRAB9ASMN1; SMN2NPC1MAOB
SCHEMBL19973586 0.86 TP53 (0.46) HTTRAB9ASMN1; SMN2NPC1MAOB
SCHEMBL19973432 0.86 TP53 (0.46) HTTRAB9ASMN1; SMN2NPC1MAOB
Hydrochloric Acid SCHEMBL19973574 0.85 TP53 (0.46) HTTRAB9ASMN1; SMN2NPC1MAOB
Hydrochloric Acid SCHEMBL19973580 0.85 TP53 (0.46) HTTRAB9ASMN1; SMN2NPC1MAOB
SCHEMBL19973454 0.85 TP53 (0.43) RAB9ASMN1; SMN2NPC1MAOBTRPV1
SCHEMBL19973630 0.85 GRM4 (0.48) RAB9ASMN1; SMN2NPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2019-07-25 US claimed
WO-2018052967-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. (US) 2018-03-22 WO claimed
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-11 US disclosed
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-11 US disclosed
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2019-07-25 US disclosed
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2019-07-25 US disclosed
WO-2018052967-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. (US) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME CBX8, HAVCR2, HCCS HTT 2199/4885RAB9A 1393/4885SMN1; SMN2 3837/4885
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same CBX8, HAVCR2, HCCS HTT 2199/4885RAB9A 1393/4885SMN1; SMN2 3837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.